Goel Niti, O'Sullivan Denis, Steinkoenig Ingrid, James Jana, Lindsay Chris A, Coates Laura C, Latella John, Ogdie Alexis, Chau Jeffrey, Bertheussen Heidi, Campbell Willemina
From Advisory Services, QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Cleveland Clinic, Cleveland, Ohio; International Dermatology Outcome Measurers, West Granby, Connecticut; Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Our Lady's Hospice and Care Services, Dublin, Ireland; Royal United Hospital, Bath; UK National Institute for Health Research (NIHR), Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; Biomedical Laboratory Sciences Program, Oslo University Hospital, Oslo, Norway; Toronto Western Hospital, Toronto, Ontario, Canada.
N. Goel, MD, Patient Research Partner, Vice President, Advisory Services, QuintilesIMS, and Adjunct Assistant Professor, Duke University School of Medicine; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; J. James, Patient Research Partner, Royal United Hospital; C.A. Lindsay, PharmD, Patient Research Partner; L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; J. Chau, BA, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association; H. Bertheussen, Patient Research Partner, Biomedical Laboratory Sciences Program, Oslo University Hospital; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital.
J Rheumatol. 2017 May;44(5):703-705. doi: 10.3899/jrheum.170152.
In line with the global trend to have disease-related organizations be more patient-centric in their approach, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) has made substantial progress incorporating patient research partners (PRP) into psoriatic arthritis and psoriasis research. Herein we summarize the involvement of PRP at the GRAPPA 2016 annual meeting. Plans for future PRP engagement were also discussed.
顺应疾病相关组织在其方法上更加以患者为中心的全球趋势,银屑病和银屑病关节炎研究与评估小组(GRAPPA)在将患者研究伙伴(PRP)纳入银屑病关节炎和银屑病研究方面取得了重大进展。在此,我们总结了PRP在GRAPPA 2016年年会上的参与情况。还讨论了未来PRP参与的计划。